Table I.
Study | Tissue source | Method of HPV detection | Histological type | HPV types detected |
---|---|---|---|---|
Asia (N = 1312) | ||||
Baba et al. (N = 77) (49) | FFPE | PCR (SPF10, Inno-LIPA) | AC, SCC | HPV 6, 16, 18, 33 |
Kinoshita et al. (N = 34) (57) | FF | PCR (TS: HPV 16, 18, 33) | AC, SCC, ASqa, LCCa, SmCCa | HPV 18 |
Iwakawa et al. (N = 275) (53) | FF | PCR (TS: HPV 16, 18, 33) | AC | HPV negative |
Hiroshima et al. (N = 49) (52) | FFPE | PCR (TS: HPV 16, 18, 33) | AC, SCC | HPV 16 |
Goto et al. (N = 296) (51) | FFPE | PCR GP5+/GP6+ | AC, SCC, CSrca | HPV 6, 11, 16, 18 |
Lim et al, 2009 (N = 99) (56) | FFPE | ISH (HPV6, 11, 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 66) | AC | HPV negative |
Miyagi et al. (N = 176) (8,9) | FFPE | PCR (TS: HPV 6, 11, 16, 18) | AC, SCC | HPV 6, 11, 16, 18 |
Hirayasu et al. (N = 73) (26) | FFPE | PCR (TS: HPV 6, 11, 16, 18) | SCC | HPV 6, 16, 18 |
Wang et al. (N = 210) (58) | FFPE, Bxb, PEb | PCR (MY09/MY11 and TS: HPV 16, 18) | AC | HPV16, HPV18 |
Tsuhako et al. (N = 23) (47) | FFPE | PCR (TS: HPV 6, 11, 16, 18) | ASq | HPV 6, 11, 16, 18 |
Adjusted HPV 16/18 prevalence (95% CI)c = 4.60% (3.48, 5.73) | ||||
Adjusted HPV 16 prevalence (95% CI)c = 1.49% (0.86, 2.11) | ||||
Adjusted HPV 18 prevalence (95% CI)c = 1.09% (0.66, 1.52) | ||||
Europe (N = 1100) | ||||
Syrjanen et al. (N = 131) (14) | FFPE | ISH (HPV6, 11, 16, 18, 30) | SCC | HPV 16, Xd |
Syrjanen et al. (N = 77) (55) | FFPE | PCR (MY09/MY11/GP5+/GP6+) | AC, SCC, other | HPV 6, 16 |
Giuliani et al. (N = 77) (13) | FFPE and FF | PCR (MY09/MY11/GP5+) | AC, SCC, ASqa, LCCa, SmCCa, NSCLCa, othera | HPV 6, 16, 18, 31, 53, |
Gorgoulis et al. (N = 68) (11) | FFPE and FF | PCR (MY09/MY11/GP5+/GP6+) | AC, SCC, LCCa | HPV negative |
Zaravinos et al. (unpublished results, N = 17) | FFPE | PCR (GP5+/GP6+) | ACe, SCCe, LCCa, NSCLCa | HPV negative |
Koshiol et al. (N = 399) (54) | FFPE | PCR (TS: HPV 16, 18; SPF10 primers (n = 92) | AC, SCC, LCC, SmCC, other | HPV 16, 18 |
Carpagnano et al. (N = 89) (34) | FFPE and BBb | PCR (consensus HPV primers) | AC, SCC, SmCC | HPV 16, 30, 31, 39, |
Nuorva et al. (N = 22) (46) | FFPE | PCR (MY09/MY11) | AC | HPV 6, 11, 16, 18, 31, 33 |
van Boerdonk et al. (N = 220) (59) | FFPE | PCR (GP5+/GP6+) | AC, SCC, LCC, NSCLCe | HPV negative |
Adjusted HPV 16/18 prevalence (95% CI)f = 3.03% (2.76, 3.30) | ||||
Adjusted HPV 16 prevalence (95% CI)f = 2.94% (2.68, 3.21) | ||||
Adjusted HPV 18 prevalence (95% CI)f = 0.82%(0.73, 0.92) | ||||
South and Central America (N = 105) | ||||
Castillo et al. (N = 36) (50) | FFPE | PCR (GP5+6+) and SB | AC, SCC, SmCCe | HPV 16, 18, 33 |
Aguayo et al. (N = 69) (48) | FFPE | PCR (GP5+/GP6+) and SB | AC, SCC | HPV 6, 16, 18, 31, 45 |
Adjusted HPV 16/18 prevalence (95% CI)f= 21.90% (19.61, 24.20) | ||||
Adjusted HPV 16 prevalence (95% CI)f = 19.18% (16.88, 21.49) | ||||
Adjusted HPV 18 prevalence (95% CI)f = 7.78% (6.61, 8.95) | ||||
North America (N = 732) | ||||
Taioli et al. (unpublished results, N = 69) | FFPE | PCR (PGMY09/PGMY11/ GP5+/6+) | AC, SCC, LCCa, NSCLCa, othere | HPV 51, X |
Pillai et al. (N = 208) (31) | FFPE | PCR (SPF10, Inno-LIPA) | AC, SCC, ASqe, LCC, othere | HPV 6, 16, 18, 39, 53, X |
Mehra et al. (N = 62) (32) | FFPE | PCR (SPF10, Inno-LIPA) | AC, SCCe, ASqa, LCCa, | HPV 6, 16, 18, 52, 53, 44, 68, 39, 74, 82, X |
Joh et al. (N = 29) (38) | FF | PCR (GP5+/GP6+) | AC, SCCe, LCCa, NSCLCa | HPV 11, 16 |
Yanagawa et al. (N = 330) (60) | FFPE | PCR (GP5+/GP6+) and ISH | AC, SCC | HPV negative |
Bohlmeyer et al. (N = 34) (45) | FFPE | PCR (MY09/MY11) | SCC | HPV 18 |
Adjusted HPV 16/18 prevalence (95% CI)f = 3.78% (3.35, 4.22) | ||||
Adjusted HPV 16 prevalence (95% CI)f = 2.03% (1.68, 2.39) | ||||
Adjusted HPV 18 prevalence (95% CI)f = 2.49% (2.23, 2.75) |
Other: histological type, not otherwise specified. AC, adenocarcinoma; ASq, adenosquamous carcinoma; BB, bronchial brushing; Bx, biopsy tissue; CSrc, carcinosarcoma; FF, fresh frozen; ISH, in situ hybridization; LCC, large cell carcinoma; NSCLC, non-small-cell lung carcinoma, not otherwise specified; PE, pleural effusion; SB, Southern blot; SmCC, small cell carcinoma; TS, type-specific primers.
aNumber of cases ≤6.
bCancer cells present and confirmed by pathologist.
cStudy is included in the model as a random effect.
dType not defined; HPV+ (for the HPV6/11/16/18/30 panel).
eNumber of cases 7–10.
fStudy is included as a covariate in the model.